Abstract
Cell therapy based on tolerogenic dendritic cells (tolDCs) is a promising tool for the treatment of type 1 diabetes (T1D). Immune assessment may allow choice of eligible autoantigens for tolDCs priming. This study aims to screen a spectrum of autoantibody (AA) and antigen specific T cells (ASCs) reactive to key pancreatic islet antigens in patients with new-onset T1D.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
